1. Home
  2. CLOV vs NUVB Comparison

CLOV vs NUVB Comparison

Compare CLOV & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clover Health Investments Corp.

CLOV

Clover Health Investments Corp.

N/A

Current Price

$4.88

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

N/A

Current Price

$4.97

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLOV
NUVB
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.1B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CLOV
NUVB
Price
$4.88
$4.97
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
$5.38
★ $13.00
AVG Volume (30 Days)
4.1M
★ 5.1M
Earning Date
11-04-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
38.03
★ 71.56
EPS
★ 0.10
N/A
Revenue
★ $1,924,308,000.00
$62,902,000.00
Revenue This Year
$53.58
$211.79
Revenue Next Year
$19.34
$45.15
P/E Ratio
$45.80
★ N/A
Revenue Growth
40.34
★ 698.96
52 Week Low
$1.58
$3.36
52 Week High
$5.59
$9.75

Technical Indicators

Market Signals
Indicator
CLOV
NUVB
Relative Strength Index (RSI) 61.59 29.49
Support Level $4.10 $4.10
Resistance Level $4.88 $5.16
Average True Range (ATR) 0.21 0.24
MACD 0.03 -0.06
Stochastic Oscillator 68.64 20.80

Price Performance

Historical Comparison
CLOV
NUVB

About CLOV Clover Health Investments Corp.

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: